D.E. Shaw & Co
JANX icon

D.E. Shaw & Co’s Janux Therapeutics JANX Stock Holding History

D.E. Shaw & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
1,096,509
+998,114
+1,014% +$14.5M 0.01% 1417
2026
Q1 		$1.37M Buy
98,395
+65,688
+201% +$901K ﹤0.01% 3197
2025
Q4 		$451K Buy
+32,707
New +$769K ﹤0.01% 3975
2024
Q4 		– Sell
-83,989
Closed -$3.82M – 4624
2024
Q3 		$3.82M Sell
83,989
-13,834
-14% -$602K ﹤0.01% 2171
2024
Q2 		$4.1M Buy
97,823
+43,185
+79% +$2.03M ﹤0.01% 2015
2024
Q1 		$2.06M Buy
+54,638
New +$1.19M ﹤0.01% 2612
2022
Q2 		– Sell
-11,480
Closed -$165K – 5541
2022
Q1 		$165K Sell
11,480
-16,291
-59% -$267K ﹤0.01% 4915
2021
Q4 		$548K Sell
27,771
-18,385
-40% -$385K ﹤0.01% 4352
2021
Q3 		$998K Buy
+46,156
New +$1.33M ﹤0.01% 3599

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

D.E. Shaw & Co's JANX Position: Q2 2026 in Review

D.E. Shaw & Co increased its Janux Therapeutics (JANX) stake by 1,014% in Q2 2026, buying an estimated $14.5M and bringing the position to 1,096,509 shares worth $16.8M. The position accounts for 0.01% of the portfolio, ranked #1417.

D.E. Shaw & Co first reported a position in JANX in Q3 2021 and has held it in 9 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • D.E. Shaw & Co held 1,096,509 shares of Janux Therapeutics worth $16.8M as of Q2 2026.
  • D.E. Shaw & Co bought 998,114 Janux Therapeutics shares in Q2 2026, an estimated $14.5M.
  • Janux Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1417 holding.
  • D.E. Shaw & Co first reported a position in Janux Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.